Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy plus camrelizumab with concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2500102158Phase 2Completed
- Sponsor
- Huizhou Central People's Hospital
- Start
- May 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Huizhou Central People's Hospital. Primary endpoint: Complete response rate after neoadjuvant chemotherapy and camrelizumab. Started May 2025; status: completed.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500102158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102158.